Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

November 1, 2028

Study Completion Date

May 1, 2029

Conditions
Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosis
Interventions
BIOLOGICAL

Debamestrocel - MSC-NTF (NurOwn)

MSC-NTF cells suspended in excipient Dulbecco Modified Eagle Medium (DMEM).

BIOLOGICAL

Placebo

Dulbecco Modified Eagle Medium (DMEM).

Trial Locations (15)

19140

Temple University Of The Commonwealth System of Higher Education, Philadelphia

32224

Mayo Clinic, Jacksonville

33328

Nova Southeastern University, Davie

33612

University of South Florida, Tampa

55905

Mayo Clinic, Rochester

60611

Northwestern Medicine, Chicago

80045

University of Colorado Anschutz Medical Campus School of Medicine, Aurora

85013

Barrow Neurological Institute, Phoenix

90033

University of Southern California, Los Angeles

92093

University of California San Diego Medical Center, La Jolla

94115

California Pacific Medical Center, San Francisco

94143

University of California, San Francisco, San Francisco

97213

Providence ALS Center, Portland

02114

Sean M. Healey & AMG Center For ALS At Massachusetts General Hospital, Boston

01655

University of Massachusetts Medical School, Worcester

Sponsors
All Listed Sponsors
lead

Brainstorm-Cell Therapeutics

INDUSTRY